Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.2200
+0.0080 (3.77%)
At close: May 6, 2026, 4:00 PM EDT
0.2112
-0.0088 (-4.00%)
Pre-market: May 7, 2026, 6:09 AM EDT
Calidi Biotherapeutics Employees
Calidi Biotherapeutics had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$882,034
Market Cap
2.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -13 | -31.71% |
| Dec 31, 2023 | 41 | 3 | 7.89% |
| Dec 31, 2022 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Virax Biolabs Group | 19 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Artelo Biosciences | 7 |
| Adial Pharmaceuticals | 5 |
CLDI News
- 7 days ago - Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI - GlobeNewsWire
- 16 days ago - Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - GlobeNewsWire
- 5 weeks ago - Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - GlobeNewsWire